title: Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
abstract: OBJECTIVE
  While regular use of low-dose aspirin has been recommended for several groups of patients at risk of vascular occlusion, the optimal dose of aspirin to produce a cardiovascular benefit whilst minimizing side effects is uncertain. Further, while enteric coated preparations may reduce gastrointestinal symptoms, the antiplatelet effects of these formulations have not been completely tested. In addition, exceptionally few data relating to these issues have been available in women.
  
  
  METHODS
  To determine whether a 100 mg alternate day dose of aspirin given in regular and enteric coated formulations for a 2-week period is sufficient to inhibit platelet function in men and women, a randomized, double-blind, placebo-controlled trial was conducted among 22 healthy volunteers evaluating the effects of these preparations on platelet aggregation induced by arachidonic acid, adenosine diphosphate, and epinephrine, and on plasma concentrations of thromboxane and prostacyclin.
  
  
  RESULTS
  During the active aspirin phase of the study, all subjects demonstrated a clinical anti-platelet effect as evidenced by failure of the platelets to aggregate in the presence of at least one platelet agonist, and mean thromboxane and prostacyclin levels decreased to 7.5 and 15.6% of baseline, respectively (both P < 0.001). After cessation of active aspirin, all subjects had fully recovery of platelet function as well as thromboxane and prostacyclin production. There were virtually no differences between regular and enteric coated formulations, or between men and women.
  
  
  CONCLUSIONS
  These data indicate that an alternate day regimen of 100 mg aspirin given in either regular or enteric coated formulation is adequate to achieve functional platelet inhibition. The clinical efficacy of this dose and formulation of aspirin is being tested in the ongoing Women's Health Study, a randomized, double-blind, placebo-controlled trial of 40000 female health professionals designed in part to assess the benefits and risks of 100 mg alternate day aspirin in the primary prevention of cardiovascular disease.
authors.affiliation: Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
authors.forename: P M
authors.initials: PM
authors.lastname: Ridker
authors.forename: C H
authors.initials: CH
authors.lastname: Hennekens
authors.forename: G H
authors.initials: GH
authors.lastname: Tofler
authors.forename: I
authors.initials: I
authors.lastname: Lipinska
authors.forename: J E
authors.initials: JE
authors.lastname: Buring
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000284:Administration, Oral; D000328:Adult; D016718:Arachidonic Acid / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage*; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004837:Epinephrine / Q000494:pharmacology; D011464:Epoprostenol / Q000096:biosynthesis / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011863:Radioimmunoassay; D012307:Risk Factors; D013931:Thromboxanes / Q000096:biosynthesis / Q000097:blood
chemical_list: D010975:Platelet Aggregation Inhibitors; D013931:Thromboxanes; D016718:Arachidonic Acid; D000244:Adenosine Diphosphate; D011464:Epoprostenol; D001241:Aspirin; D004837:Epinephrine